首页> 外国专利> ISOLATED MONOCLONAL ANTIBODY, HUMANIZED AND CHEMICAL ANTIBODY OF ISOLATED MONOCLONAL ANTIBODY, ISOLATED HYBRIDOMA CELL LINE, METHOD FOR INITIATING YOUR CYTOTOXIDITY INDUCED BY HUMOROUS HUMAN HUMAN EMERGED CYTOTOXIDE ANTIBODY USES OF A MONOCLONAL ANTIBODY OR ITS CDMAB, ALONE OR IN CONJECTION WITH AT LEAST ONE CHEMOTHERAPEUTIC AGENT, AND COMPOSITION

ISOLATED MONOCLONAL ANTIBODY, HUMANIZED AND CHEMICAL ANTIBODY OF ISOLATED MONOCLONAL ANTIBODY, ISOLATED HYBRIDOMA CELL LINE, METHOD FOR INITIATING YOUR CYTOTOXIDITY INDUCED BY HUMOROUS HUMAN HUMAN EMERGED CYTOTOXIDE ANTIBODY USES OF A MONOCLONAL ANTIBODY OR ITS CDMAB, ALONE OR IN CONJECTION WITH AT LEAST ONE CHEMOTHERAPEUTIC AGENT, AND COMPOSITION

机译:分离的单克隆抗体,人源化和化学分离的单克隆抗体,分离的纤毛细胞系的人源和化学抗体和组成

摘要

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
机译:本发明涉及一种使用新型筛选范例产生癌症疾病修饰抗体的方法。通过使用癌细胞的细胞毒性作为终点分离抗癌抗体,该方法使得产生用于治疗和诊断目的的抗癌抗体成为可能。抗体可用于辅助癌症的分期和诊断,并可用于治疗原发性肿瘤和肿瘤转移。可以将抗癌抗体与毒素,酶,放射性化合物和血细胞结合。

著录项

  • 公开/公告号BRPI0718644A2

    专利类型

  • 公开/公告日2013-11-26

    原文格式PDF

  • 申请/专利权人 ARIUS RESEARCH INC.;

    申请/专利号BR2007PI18644

  • 申请日2007-11-13

  • 分类号C12N5/18;A61K39/395;A61K47/48;A61K51/10;A61P35;A61P37/04;C07K16/18;C07K16/30;C07K16/46;C12P21/08;G01N33/574;G01N33/577;

  • 国家 BR

  • 入库时间 2022-08-21 15:58:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号